Postoperative Adjuvant TACE Treatment in CK18 Positive Patients
To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the necessity of postoperative adjuvant TACE.
Postoperative Adjuvant TACE|Hepatocellular Carcinoma.
Overall survival, 3 years
Time to recurrence, 3 years
To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the necessity of postoperative adjuvant TACE.